Clinical Trials Logo

Radiation Dermatitis clinical trials

View clinical trials related to Radiation Dermatitis.

Filter by:

NCT ID: NCT06158347 Recruiting - Breast Cancer Clinical Trials

Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation Dermatitis in Patients With Localized Breast Cancer

HBOT
Start date: November 6, 2023
Phase: N/A
Study type: Interventional

This study aimed to evaluate reducing the incidence of radiation dermatitis by assigning hyperbaric oxygen therapy to patients with localized breast cancer.

NCT ID: NCT06040983 Not yet recruiting - Breast Cancer Clinical Trials

Clinical Investigation on the Treatment of Radiation Induced Dermatitis With FR-101 Chest Dressing

Start date: September 18, 2023
Phase: N/A
Study type: Interventional

Breast cancer is the top one incidence of cancer in women. Whole breast radiation therapy plays an indispensable role in the course of breast cancer treatment, and the radiation dermatitis is the major side effect affected quality of life. Radiation dermatitis can be divided into acute and chronic. Severe acute radiation dermatitis affects the quality of life of patients during the course of treatment, and may cause treatment interruption and affect the efficacy. Chronic radiation dermatitis may cause irreversible skin problems, and lead to so-called "radiation-irritated skin" (radiation-irritated skin) seriously affects the quality of life of breast cancer patients after treatment. This study will enroll 30 breast cancer patients who received whole breast radiation therapy after breast conserving surgery. Subject will receive FR-101 chest dressing and be instructed to use the product on the target skin area accepted radiation therapy once every 2 days, taking care of avoiding applications from 1 to 4 h before treatment to prevent "Build-up" effect. Subjects will need to come back to clinics for assessment weekly during radiotherapy, 2 weeks after radiotherapy, and 6 weeks after radiotherapy. The evaluation includes physical examinations, questionnaire surveys, skin observation and measurements, and photographs. The total study time is at least 3 months. The target area of radiation-irritated skin condition will be observed and graded according to CTCAE rate. The skin physiological parameters will be detected by MoistureMeter SC, Vapometer, SkinColorCatch and HX-YL001 infrared thermometer. Statistical analysis of skin physiological parameters is used to evaluate the efficacy of FR-101 chest dressing on the prevention of acute radiation dermatitis after radiotherapy.

NCT ID: NCT06001463 Completed - Clinical trials for Radiation Dermatitis

Clinical Trial of CSMed Wound Dressing for Radiation Dermatitis

Start date: June 1, 2020
Phase: Phase 1
Study type: Interventional

Investigate the effects of CSMed® for preventing and managing radiation dermatitis in patients with Breast cancer and Head-Neck cancer receiving radiotherapy (≥50 Gy).

NCT ID: NCT05810194 Completed - Clinical trials for Radiation Dermatitis

Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis

Start date: May 1, 2023
Phase:
Study type: Observational

Routinely collected data on radiation-induced skin toxicity from 2010 to 2022 will be retrospectively analyzed. Data will be split into two cohorts: patients that received 1) StrataXRT and 2) standard of care. The incidence of grade ≥ 2 radiation dermatitis, the time to onset of grade ≥ 2 radiation dermatitis, the radiation dose at onset of grade ≥ 2 radiation dermatitis, the incidence of moist desquamation and the number of treatment interruptions will be compared between the cohorts.

NCT ID: NCT05693597 Completed - Clinical trials for Radiation Dermatitis

Evaluation of the Effect of Nigella Sativa for the Prophylaxis to Radiation Induced Dermatitis in Breast Cancer Patients

Start date: January 24, 2023
Phase: Phase 2
Study type: Interventional

Radiation induced dermatitis (RID) is one of the leading adverse events of radiation therapy, and if occurred could alter the course of therapy. The main pathways of RID is inflammation and oxidative stress on local and systemic bases. Nigella sativa is an herbal medicine whose anti-inflammatory and antioxidant activities have been proven in several clinical trials. Thus, the aim of the present study is to evaluate the efficacy of Nigella sativa as a prophylactic method against the development of RID.

NCT ID: NCT05607225 Recruiting - Clinical trials for Head and Neck Cancer

Deep Learning-based Classification and Prediction of Radiation Dermatitis in Head and Neck Patients

Start date: July 1, 2022
Phase:
Study type: Observational

to develop a deep learning-based model to grade the severity of radiation dermatitis (RD) and predict the severity of radiation dermatitis in patients with head and neck cancer undergoing radiotherapy, so as to provide support for doctors' diagnosis and prediction.

NCT ID: NCT05594498 Recruiting - Breast Cancer Clinical Trials

A Study of StrataXRT in the Prevention of Radiation Dermatitis in Breast Cancer Patients

Start date: October 13, 2022
Phase: N/A
Study type: Interventional

For breast cancer patients undergoing adjuvant radiotherapy, radiation dermatitis (RD) is a common occurrence that can negatively impact patients' quality of life (QOL). RD often presents as erythema, pruritus, and/or edema and in more severe cases, skin breakage can occur, resulting in moist desquamation. StrataXRT is a silicone-based film-forming topical gel. Recent studies have shown the benefits of StrataXRT, but with mixed results. A recent randomized controlled trial published in 2022 found that in breast cancer patients (n=100), the use of StrataXRT significantly reduced the mean size of the radiation-induced dermatitis area (p=0.002) when compared to the control group. Additionally, another study (n=49) demonstrated significant differences in the Erythema Index (EI) (p=0.001) and Melanin Index (MI) (p=0.005) between StrataXRT compared to the use of Xderm, a moisturizer cream. To validate the finding of the previous studies a pilot study testing the efficacy of StrataXRT has been proposed. In this study, 50 patients will use Strata XRT on their breast/chest wall during radiation treatment. Their skin will be assessed throughout and post-treatment. Investigators hypothesize the severity of skin reactions will be less for patients using Strata XRT when compared to historical data from our centre.

NCT ID: NCT05553392 Recruiting - Clinical trials for Radiation Dermatitis

StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to assess the efficacy and safety of StrataXRT® in comparison to standard of care (defined using the Common Terminology Criteria for Adverse Events [CTCAE], version 5.0) by assessing the severity of inguinal RD in patients receiving elective radiation therapy +/- systemic therapy to the bilateral inguinal nodes.

NCT ID: NCT05505214 Withdrawn - Clinical trials for Radiation Dermatitis

Topical Steroids & Bacterial Decolonization for Radiation Dermatitis

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether bacterial decolonization of the nares and skin, topical steroid therapy, or a combination of the two regimens prior to treatment with radiotherapy (RT) for breast and head and neck cancer patients can prevent grade 2 or higher grade radiation dermatitis (RD) graded via the Common Terminology Criteria for Adverse Events (CTCAE) scale and improve quality of life.

NCT ID: NCT05450848 Completed - Clinical trials for Radiation Dermatitis

StrataXRT vs. Standard Clinical Practice in the Prevention and Treatment of Radiation Dermatitis

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Current clinical practice for preventing and treating radiation dermatitis across Queensland (QLD) Health Radiation Oncology departments involves the application of aqueous cream daily to the skin of the treatment site, commencing from Day 1 of EBRT. The primary aim of this study is to assess the efficacy of StrataXRT when compared to current clinical practice in preventing and managing radiation dermatitis.